Michael Wacker

Polyneuron is a growing Basel-based biotechnology company active in the area of autoimmune disease treatments. The company was founded in 2014 as a spinout company from the University of Basel to develop novel treatments to combat immune disorders using its Antibody-Catch™ technology platform. The company currently employs about 10 people and has raised a significant amount in equity funding from top-tier VCs. We are a team of passionate and experienced scientists, entrepreneurs and investors willing to bring new therapies to patients.

LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK.

GlycoVaxyn is a private Swiss biotechnology company developing a broad portfolio of novel bioconjugate vaccines to prevent and treat common, severe bacterial infections using its proprietary glycoprotein technology.

We put health at the heart of our work. Biomed is a leading Swiss early-stage VC at the center of European biotech. We build companies around the most intriguing innovation. We strive to enable founders and their ideas. We work together on a basis of equality - as a team and with entrepreneurs. We focus on scientific excellence, building strong companies to create medical and commercial value and bring new medicines to market that improve patient’s lives.

We invest in innovative private early- to mid-stage human Life Science companies that address important medical needs with novel technologies or products backed by compelling science and with differentiated advantages over current treatment options. Our focus is on Switzerland and surrounding EU countries Germany, Austria, France, Italy and Benelux. We mostly invest in drug development and, to a lesser degree, in diagnostics and medical technology. The amount we aim to invest over the life time of our portfolio companies is up to CHF 10 million. BioMedPartners often plays the lead or co-lead investor role structuring the transaction and syndicating with other venture capital firms.

Polyneuron is a growing Basel-based biotechnology company active in the area of autoimmune disease treatments. The company was founded in 2014 as a spinout company from the University of Basel to develop novel treatments to combat immune disorders using its Antibody-Catch™ technology platform. The company currently employs about 10 people and has raised a significant amount in equity funding from top-tier VCs. We are a team of passionate and experienced scientists, entrepreneurs and investors willing to bring new therapies to patients.